The era of high-dose chemotherapy for breast cancer: Revisiting a troubled quest

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3205-3206

  Borges, Virginia F ^a   Elias, Anthony D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; DOSE RESPONSE; DRUG MEGADOSE; EDITORIAL; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 80051979837     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.1303     Document Type: Editorial

References (5)

1. Frei E. 3rd, Canellos G.P.: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980
2. Peters W.P., Shpall E.J., Jones R.B., et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1376, 1988 (Pubitemid 19089024)
3. Antman K., Ayash L., Elias A., et al: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102-110, 1992
4. Berry D.A., Ueno N.T., Johnson M.M., et al: High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials. J Clin Oncol 29:3214-3223, 2011
5. Berry D.A., Ueno N.T., Johnson M.M., et al: High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: Overview of six randomized trials. J Clin Oncol 29:3224-3231, 2011